← Back to patent-cliff list
Chiglitazar Sodium
Tier C — Watch / tradeChiglitazar Sodium
Shenzhen Chipscreen Biosciences Co., Ltd.
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PPARα, PPARγ, PPARδ
Brand：Bilessglu
Indications (approved)：Type 2 diabetes
Regional status
US
-
EU
-
China
Approved
2021-10-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Chiglitazar Sodium?
Approved indications include: Type 2 diabetes.
When does the Chiglitazar Sodium patent expire?
No public expiry year is available for Chiglitazar Sodium yet; this page updates once verified.
How do I get a quote for Chiglitazar Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27